-
-
Nearly 40 Institutions Participated in Aimei Vaccine's Investor Open Day Event
2023-12-28On December 27, Aimei Vaccine announced that it held an investor open day event on December 22. Almost 40 investment institutions, including CITIC Securities, CITIC Construction Investment Securities, Guotai Junan Securities, and CMB International Securities, visited and toured Aimei's bacterial vaccine industrialization base and mRNA and viral vaccine industrialization production base in Ningbo. They engaged in on-site visits, discussions, and exchanges, gaining detailed insight into the upcoming innovative vaccine products slated for market launch and their production workshop construction, as well as understanding the layout and development plans of the company's product pipeline.
-
-
-
Strategic Collaboration Initiated between Aimei Vaccine and China Foundation for Viral Hepatitis, Jointly Promoting the Elimination of Hepatitis Threats
2023-12-08Aimei Vaccine took a significant and important step toward "responding to the WHO's action to eliminate the threat of viral hepatitis by 2030." On December 6, Aimei Vaccine formally entered into a strategic cooperation agreement with the China Foundation for Viral Hepatitis (hereinafter referred to as "the Foundation") to jointly promote the elimination of hepatitis threats in China.
-
-
-
Two Types of mRNA COVID-19 Vaccines Produced by AIM Vaccine was Approved for Clinical Test in Pakistan
2023-02-15 -
On February 13, 2023, the candidate mRNA vaccine for COVID-19 virus variant strain produced by AIM Vaccine was officially approved for Phase-I clinical test in Pakistan. On the same day, the candidate mRNA vaccine for COVID-19 prime strain produced by our group was officially approved for Phase-III clinical test for sequential booster shot in Pakistan.
-
-
-
Rongan Biological was Selected on the List of Specialized, Refined, Differentiated and Innovative “Little Giant” Key Incubation Enterprises in Ningbo in 2023
2023-02-15 -
A few days ago, Ningbo Municipal Bureau of Economy and Information Technology issued an announcement that 650 enterprises were determined as specialized, refined, differentiated and innovative “Little Giant” key incubation enterprises in Ningbo in 2023, including Ningbo Rongan Biomedicine Co., Ltd. subordinate to AIM Vaccine.
-
-
-
AIM Vaccine Joins Hands with Fortune Global 500 Enterprises to Create the Global Industrial Highland for “Intelligent Manufacturing of New Medicine” in Beijing Economic-Technological Development Area
2023-02-15 -
On the morning of February 14, Beijing Economic-Technological Development Area held the Global Partner Conference on “Intelligent Manufacturing of New Medicine” and declared that it would accelerate the construction of a global industrial highland for “intelligent manufacturing of new medicine”. AIM Vaccine, together with a group of Fortune Global 500 enterprises such as Bayer, Sanofi, GE Healthcare, and Varian, as well as domestic leading bio-medical enterprises, attended the signing ceremony at the conference.
-
-
-
AIM Vaccine Rises on its First Day on HKEx Main Board
2022-10-12 -
AIM Vaccine Co., Ltd. (06660.HK) closed at HK$ 16.66, up 3.09%, on October 6, its first day on HKEx Main Board.
-
-
-
Phase II Clinical Data on AIM’s mRNA Impressive and Significantly Effective On Omicron
2022-08-24 -
The data from the phase II clinical trial of mRNA (LVRNA009) targeting Covid-19 - independently developed by AIM Vaccine, have been known to the public. The live virus-neutralizing antibodies tested by Wuhan Institute of Virology, CAS, revealed that, the geometric mean titer (GMT) of the live virus-neutralizing antibodies 14 days after full-course vaccination of mRNA, was 994.9 in the adult medium-dose group and 1405.7 in the adult high-dose group. These figures prove mRNA is fairly strong in immunogenicity. Of note, the independent third-party tests indicate mRNA (LVRNA009) could fend off Omicron variants to a great extent.
-
-
-
Upgrade for Higher Safety ▏AIM Rong’an Submitted Clinical Application for Serum-free Human Rabies Vaccine to CDE
2021-12-15 -
Rong’an Bio, a wholly-owned subsidiary of AIM Vaccine, has submitted its application of communication session for the freeze-dried rabies vaccine for human use (serum-free Vero cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. As an upgrade, the serum-free Vero cell human rabies vaccine is most prominently characterized by serum-free cell culture, which results in higher safety.
-